Image

Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations

Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized "life book." The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.

Description

Pre-human development (in silico; not part of the clinical trial):

Prior to human participation, the Aurora system underwent an in-silico preparatory phase focused on content coherence and emotional safety using synthetic user profiles. Simulated interactions were reviewed by licensed mental health professionals to identify potential safety concerns and inform iterative refinements of the supportive narrative process. This preparatory work did not involve human participants and is not part of the clinical trial.

Human participants (clinical trial):

The study uses a sequential, non-randomized, three-arm interventional design with a total anticipated sample of 55 participants.

Arm 1: Healthy adults (single-session arm; n=20) Following informed consent, participants complete a single guided interaction with Aurora to generate a brief personal narrative. Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF), perceived usefulness and user experience, usability (System Usability Scale, SUS), satisfaction, and qualitative feedback.

Arm 2: Adults with DSM-5 diagnosed mental disorder in residential care (4-hour intervention arm; n=15) Following informed consent, participants complete four guided sessions over two weeks (two sessions per week, 1 hour per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.

Arm 3: Healthy older adults (aged 65 years and older; 4-hour intervention arm; n=20) Following informed consent, participants complete two guided sessions over two weeks (one session per week, 2 hours per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.

Data security and compliance:

All interactions occur in a secure professional environment. Textual data are pseudonymized during transcription and fully anonymized at the end of the project. Optional audio recordings are stored on encrypted offline devices and deleted after integration into the participant's life book. The study complies with applicable data protection and regulatory frameworks, including GDPR (EU 2016/679), LOPDGDD 3/2018, the EU AI Act (2024/1689), and institutional ethics guidelines.

Eligibility

Inclusion Criteria

Arm 1: Healthy Adults (Single-Session Intervention)

Age 18 years or older at screening.

Sufficient ability to read and understand Spanish to follow study instructions and complete questionnaires.

Ability to engage in a brief guided interaction and complete self-report measures.

Able and willing to provide written informed consent.

\---

Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care (4-hour Intervention)

Age 18 years or older at screening.

Currently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period.

Documented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician.

Minimal clinical stability at baseline, defined as all of the following:

Clinically stable in the judgment of the treating clinician.

No requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks.

Clinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability.

Sufficient ability to understand spoken and written Spanish to participate in study procedures.

Ability to engage in guided interaction and provide feedback.

Able and willing to provide informed consent; when applicable, provision of legal guardian consent plus participant assent.

Willingness to participate in all study procedures.

\---

Arm 3: Healthy Older Adults (≥65 Years; 4-hour Intervention)

Age 65 years or older at screening.

No self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).

Sufficient ability to read and understand Spanish to participate in study procedures.

Adequate cognitive and communication abilities to engage in guided interaction and complete questionnaires.

Able and willing to provide written informed consent.

\---

Exclusion Criteria

Arm 1: Healthy Adults

Current acute medical or psychiatric condition that would compromise safe participation or data validity.

Moderate or high acute suicide or self-harm risk at screening.

Significant cognitive, communication, or comprehension impairment that would interfere with participation.

Explicit refusal to participate.

\---

Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care

Current acute psychiatric decompensation requiring crisis-level care.

Moderate or high acute suicide or self-harm risk at screening or baseline.

High risk of clinically significant emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is contraindicated due to one or more of the following:

Severe clinical destabilization within the past 3 months.

Trauma-related re-experiencing symptoms.

Marked dissociative symptoms.

Inability to provide informed consent, with no legal representative available when required, or lack of participant assent when applicable.

Significant cognitive, communication, or comprehension impairment without available supports.

Explicit refusal to participate.

Imminent discharge or transfer that would prevent completion of the intervention or post-assessment.

\---

Arm 3: Healthy Older Adults

Self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).

Moderate or high acute suicide or self-harm risk at screening.

Current acute medical or psychiatric condition that would compromise safe participation.

Significant cognitive, communication, or comprehension impairment that would interfere with participation.

Explicit refusal to participate.

Study details
    Institutionalization
    Elderly
    Mental Health
    Wellbeing
    Aging

NCT07494110

Universitat Autonoma de Barcelona

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.